Actual Situation and Characteristics of Pharmacotherapy for Glucocorticoid-induced Osteoporosis Prevention
-
- Seiki Shizuno
- Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University
-
- Yamashita Shuji
- Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University Gifu Pharmaceutical University Pharmacy
-
- Kaburaki Miho
- Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University
-
- Tamaki Hirofumi
- Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
-
- Noguchi Yoshihiro
- Gifu Pharmaceutical University Pharmacy Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University
-
- Osanai Arihiro
- Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
-
- Ino Yoko
- Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
-
- Iguchi Kazuhiro
- Gifu Pharmaceutical University Pharmacy Laboratory of Community Pharmacy, Gifu Pharmaceutical University
-
- Teramachi Hitomi
- Gifu Pharmaceutical University Pharmacy Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University
-
- Hayashi Hideki
- Laboratory of Pharmacy Practice and Community Healthcare, Gifu Pharmaceutical University Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University
Bibliographic Information
- Other Title
-
- ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴
Search this article
Description
<p>Glucocorticoid-induced osteoporosis (GIO) is a serious side effect of long-term glucocorticoid (GC) administration. However, sufficient high compliance rate data for the guidelines on the management and treatment of GIO in Japan is unavailable. Additionally, GC is prescribed at many medical departments involved in outpatient care. Community pharmacists might intervene to support more appropriate pharmacotherapy to avoid GIO. This study examines the actual state and characteristics of pharmacotherapy for GIO prevention. We investigated 136 patients from the Gifu Pharmaceutical University pharmacy that received GC treatment continuously for over three months. We obtained the age, GC dosage, and combined medications data retrospectively from the electronic drug system and assessed the fracture risk factor using a scoring system. One hundred and two patients were recommended for prophylactic pharmacotherapy based on the guidelines on the management and treatment of GIO. Nineteen patients (18.6%) did not receive this therapy. Thus, community pharmacists should consider proposing prescriptions using the guidelines and help support GIO prevention.</p>
Journal
-
- Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
-
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 49 (2), 66-73, 2023-02-10
Japanese Society of Pharmaceutical Health Care and Sciences
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390299130048533888
-
- ISSN
- 18821499
- 1346342X
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed